On March 9, 2022 Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, reported that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three investor conferences in March 2022 (Press release, Fortress Biotech, MAR 9, 2022, View Source [SID1234609811]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

34th Annual ROTH Conference: The company will participate in a fireside chat on Monday, March 14, 2022, at 3:00 p.m. PT and will attend one-on-one meetings during the conference. A webcast of the fireside chat will be available on the Events page under the News & Media section of Fortress’ website: www.fortressbiotech.com for approximately 30 days following the chat.
Oppenheimer’s 32nd Annual Virtual Healthcare Conference: The company will present on Wednesday, March 16, 2022, at 8:40 a.m. ET and will participate in one-on-one meetings during the conference. A webcast of the presentation will be available on the Events page under the News & Media section of Fortress’ website: www.fortressbiotech.com for approximately 30 days following the meeting.
Cantor Fitzgerald’s Rare Orphan Disease Summit: The company will participate in a panel presentation on Wednesday, March 30, 2022, at 8:30 a.m. ET, titled, "Beyond The One-Hit Wonder: How To Build A Rare Disease Pipeline."